Aceclofenac use restricted

on the 13 February 2015

Further information
MHRA Drug Safety Update

The use of aceclofenac is now contraindicated in patients with certain established cardiovascular diseases, including ischaemic heart disease, peripheral arterial disease, cerebrovascular disease and congestive heart failure. Treatment with the drug should be initiated only after careful consideration of any significant cardiovascular risk factors.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

More from MIMS

Omega-3 supplements withdrawn from secondary prevention use

Omega-3 supplements withdrawn from secondary prevention use

Omega-3 fatty acids can no longer be prescribed to...

MIMS supplement on contraception and HRT

MIMS supplement on contraception and HRT

The December issue of MIMS includes a special supplement...

Drug shortages - live tracker

Drug shortages - live tracker

Added: clonidine.
Use our constantly updated shortages...

Prescribers reassured over metformin contamination

Prescribers reassured over metformin contamination

Trace amounts of the potential carcinogen N-nitrosodimethylamine...